Sign in or create an account to add this stock to your watchlist.
About Alimera Sciences (NASDAQ:ALIM)
Alimera Sciences, Inc., a pharmaceutical company, engages in the research, development, and commercialization of prescription ophthalmic pharmaceuticals in the United States and internationally. It focuses on diseases affecting the back of the eye or retina. The company offers ILUVIEN, an intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and could lead to severe vision loss and blindness. Its ILUVIEN is inserted in the back of the patient's eye in a non-surgical procedure, which allows for a self-sealing wound by delivering a continuous microdose of the non-proprietary corticosteroid fluocinolone acetonide in the eye. The company has an agreement with pSivida US, Inc. for the development and sale of ILUVIEN, and a proprietary insert technology to deliver other corticosteroids to the back of the eye for the treatment and prevention of eye diseases in humans or to treat DME. It sells its products through sales force, as well as through distributors. The company serves physician offices, pharmacies, and hospitals. Alimera Sciences, Inc. was founded in 2003 and is headquartered in Alpharetta, Georgia.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:ALIM
CUSIPN/A
Phone678-990-5740
Debt
Debt-to-Equity Ratio-0.62
Current Ratio4.81
Quick Ratio4.64
Price-To-Earnings
Trailing P/E Ratio-2.67
Forward P/E Ratio-2.58
P/E GrowthN/A
Sales & Book Value
Annual Sales$35.91 million
Price / Sales1.51
Cash FlowN/A
Price / CashN/A
Book Value($0.86) per share
Price / Book-0.90
Profitability
EPS (Most Recent Fiscal Year)($0.29)
Net Income$-22,000,000.00
Net Margins-58.69%
Return on EquityN/A
Return on Assets-32.59%
Miscellaneous
Employees126
Outstanding Shares70,040,000
Alimera Sciences (NASDAQ:ALIM) Frequently Asked Questions
What is Alimera Sciences' stock symbol?
Alimera Sciences trades on the NASDAQ under the ticker symbol "ALIM."
How were Alimera Sciences' earnings last quarter?
Alimera Sciences Inc (NASDAQ:ALIM) released its quarterly earnings data on Wednesday, February, 28th. The biopharmaceutical company reported ($0.10) EPS for the quarter, missing the consensus estimate of ($0.03) by $0.07. The biopharmaceutical company had revenue of $9.14 million for the quarter, compared to analyst estimates of $9.60 million. View Alimera Sciences' Earnings History.
When is Alimera Sciences' next earnings date?
What price target have analysts set for ALIM?
2 brokerages have issued 1 year target prices for Alimera Sciences' shares. Their predictions range from $3.00 to $3.00. On average, they anticipate Alimera Sciences' stock price to reach $3.00 in the next year. View Analyst Ratings for Alimera Sciences.
What are Wall Street analysts saying about Alimera Sciences stock?
Here are some recent quotes from research analysts about Alimera Sciences stock:
- 1. According to Zacks Investment Research, "Alimera Sciences, Inc., based in Alpharetta, Georgia, is a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals. The Company is presently focused on diseases affecting the back of the eye, or retina because it believes these diseases are not well treated with current therapies and represent a significant market opportunity. Its product candidate Iluvien(R) is an intravitreal insert containing fluocinolone acetonide, a non-proprietary corticosteroid with demonstrated efficacy in the treatment of ocular disease. Iluvien is in development for the treatment of diabetic macular edema (DME). DME is a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness. " (5/11/2018)
- 2. Cowen Inc analysts commented, "Adaptimmune reported Q3 financials including net loss of $1MM and a cash balance." (11/2/2017)
Who are some of Alimera Sciences' key competitors?
Some companies that are related to Alimera Sciences include Neos Therapeutics (NEOS), VERONA PHARMA P/S (VRNA), Xoma (XOMA), Menlo Therapeutics (MNLO), Ovid Therapeutics (OVID), Immune Design (IMDZ), Kamada (KMDA), POXEL (PXXLF), Mustang Bio (MBIO), Ra Pharmaceuticals (RARX), Synlogic (SYBX), Marinus Pharmaceuticals (MRNS), Molecular Templates (MTEM), Summit Therapeutics (SMMT) and Avid Bioservices (CDMO).
Who are Alimera Sciences' key executives?
Alimera Sciences' management team includes the folowing people:
- Mr. Charles Daniel Myers, Co-Founder, Chief Exec. Officer and Director (Age 64)
- Mr. Richard S. Eiswirth Jr., Pres & CFO (Age 50)
- Dr. Kenneth Green Ph.D., Chief Scientific Officer, Global Head of R&D and Sr. VP (Age 60)
- Mr. David R. Holland, Co-Founder and Sr. VP of Sales & Marketing (Age 54)
- Mr. Jeffrey W. Burris, VP, Gen. Counsel and Sec. (Age 46)
Has Alimera Sciences been receiving favorable news coverage?
Media headlines about ALIM stock have trended somewhat positive this week, Accern reports. Accern scores the sentiment of media coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Alimera Sciences earned a coverage optimism score of 0.09 on Accern's scale. They also assigned media headlines about the biopharmaceutical company an impact score of 47.80 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company's share price in the next several days.
Who are Alimera Sciences' major shareholders?
Alimera Sciences' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include JW Asset Management LLC (0.99%). Company insiders that own Alimera Sciences stock include Armistice Capital Master Fund, Armistice Capital, Llc, C Daniel Myers, Philip Ashman and Richard S Eiswirth Jr. View Institutional Ownership Trends for Alimera Sciences.
Which major investors are selling Alimera Sciences stock?
ALIM stock was sold by a variety of institutional investors in the last quarter, including JW Asset Management LLC. Company insiders that have sold Alimera Sciences company stock in the last year include C Daniel Myers, Philip Ashman and Richard S Eiswirth Jr. View Insider Buying and Selling for Alimera Sciences.
How do I buy shares of Alimera Sciences?
Shares of ALIM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Alimera Sciences' stock price today?
One share of ALIM stock can currently be purchased for approximately $0.7731.
How big of a company is Alimera Sciences?
Alimera Sciences has a market capitalization of $54 million and generates $35.91 million in revenue each year. The biopharmaceutical company earns $-22,000,000.00 in net income (profit) each year or ($0.29) on an earnings per share basis. Alimera Sciences employs 126 workers across the globe.
How can I contact Alimera Sciences?
Alimera Sciences' mailing address is 6120 WINDWARD PARKWAY STE 290, ALPHARETTA GA, 30005. The biopharmaceutical company can be reached via phone at 678-990-5740 or via email at [email protected]
MarketBeat Community Rating for Alimera Sciences (ALIM)
MarketBeat's community ratings are surveys of what our community members think about Alimera Sciences and other stocks. Vote "Outperform" if you believe ALIM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ALIM will underperform the S&P 500 over the long term. You may vote once every thirty days.
Alimera Sciences (NASDAQ:ALIM) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
2 Wall Street analysts have issued ratings and price targets for Alimera Sciences in the last 12 months. Their average twelve-month price target is $3.00, suggesting that the stock has a possible upside of 288.05%. The high price target for ALIM is $3.00 and the low price target for ALIM is $3.00. There are currently 2 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 3.00 | 3.00 | 3.00 | 3.00 |
| Ratings Breakdown: | 0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $3.00 | $4.00 | $4.00 | $4.00 |
| Price Target Upside: | 288.05% upside | 233.33% upside | 233.33% upside | 222.58% upside |
Alimera Sciences (NASDAQ:ALIM) Consensus Price Target History
Alimera Sciences (NASDAQ:ALIM) Analyst Ratings History
Show:
| Date | Brokerage | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 5/8/2018 | HC Wainwright | Set Price Target | Buy | $3.00 | High |  |
| 11/2/2017 | Cowen | Reiterated Rating | Buy | | N/A | |
| 4/27/2017 | Rodman & Renshaw | Initiated Coverage | Buy ➝ Buy | $4.00 | High | |
(Data available from 5/23/2016 forward)
Alimera Sciences (NASDAQ:ALIM) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Alimera Sciences (NASDAQ ALIM) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 14.70%
Institutional Ownership Percentage: 49.63%
Alimera Sciences (NASDAQ ALIM) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 5/7/2018 | Richard S Eiswirth Jr | Insider | Buy | 10,000 | $1.05 | $10,500.00 | 171,770 | |
| 2/6/2018 | Armistice Capital Master Fund | Major Shareholder | Buy | 20,000 | $1.14 | $22,800.00 | | |
| 2/2/2018 | Armistice Capital, Llc | Major Shareholder | Buy | 8,000 | $1.16 | $9,280.00 | | |
| 1/19/2018 | C. Daniel Myers | CEO | Sell | 52,900 | $1.20 | $63,480.00 | 101,511 | |
| 1/19/2018 | Philip Ashman | SVP | Sell | 25,500 | $1.20 | $30,600.00 | 12,750 | |
| 1/19/2018 | Richard S Eiswirth Jr | Insider | Sell | 13,410 | $1.20 | $16,092.00 | 84,779 | |
| 1/17/2018 | C. Daniel Myers | CEO | Sell | 52,900 | $1.23 | $65,067.00 | 154,411 | |
| 1/17/2018 | Philip Ashman | SVP | Sell | 25,500 | $1.23 | $31,365.00 | 38,250 | |
| 1/17/2018 | Richard S Eiswirth Jr | Insider | Sell | 14,494 | $1.23 | $17,827.62 | 98,619 | |
| 3/10/2017 | C. Daniel Myers | CEO | Sell | 21,172 | $1.39 | $29,429.08 | 180,861 | |
| 9/15/2016 | Richard S Eiswirth Jr | Insider | Sell | 51,471 | $1.51 | $77,721.21 | 86,445 | |
| 4/21/2016 | L.P. Bavp | Major Shareholder | Sell | 478,673 | $2.59 | $1,239,763.07 | 4,477,291 | |
| 12/16/2015 | Richard S. Eiswirth, Jr. | CFO | Sell | 46,669 | $2.31 | $107,805.39 | 34,974 | |
| 12/8/2015 | James E Flynn | Insider | Buy | 272,249 | $3.01 | $819,469.49 | | |
| 12/3/2015 | James E Flynn | Insider | Buy | 243,252 | $3.00 | $729,756.00 | | |
| 10/30/2015 | James E Flynn | Insider | Buy | 16,542 | $3.00 | $49,626.00 | | |
| 10/28/2015 | James E Flynn | Insider | Buy | 59,342 | $3.00 | $178,026.00 | | |
| 10/26/2015 | James E Flynn | Insider | Buy | 60,364 | $3.00 | $181,092.00 | | |
| 10/21/2015 | James E Flynn | Major Shareholder | Buy | 160,684 | $3.00 | $482,052.00 | | |
| 10/20/2015 | James E Flynn | Major Shareholder | Buy | 100,130 | $3.00 | $300,390.00 | | |
| 10/19/2015 | James E Flynn | Major Shareholder | Buy | 129,226 | $2.92 | $377,339.92 | | |
| 10/15/2015 | Richard S. Eiswirth, Jr. | CFO | Sell | 13,625 | $2.69 | $36,651.25 | 34,974 | |
| 10/9/2015 | James E Flynn | Insider | Buy | 321,785 | $2.42 | $778,719.70 | | |
| 9/3/2015 | Calvin W Roberts | Director | Buy | 6,424 | $3.00 | $19,272.00 | 6,389 | |
| 8/21/2015 | Kenneth Green | SVP | Sell | 20,000 | $3.29 | $65,800.00 | 48,235 | |
| 8/17/2015 | Kenneth Green | SVP | Sell | 20,000 | $3.90 | $78,000.00 | 68,235 | |
| 6/26/2015 | L.P. Bavp | Major Shareholder | Sell | 1,024 | $5.00 | $5,120.00 | | |
| 6/19/2015 | L.P. Bavp | Major Shareholder | Sell | 5,568 | $5.00 | $27,840.00 | | |
| 5/1/2015 | C. Daniel Myers | CEO | Sell | 2,000 | $4.37 | $8,740.00 | | |
| 4/27/2015 | L.P. Bavp | Major Shareholder | Sell | 3,114 | $5.02 | $15,632.28 | | |
| 4/23/2015 | L.P. Bavp | Major Shareholder | Sell | 4,362 | $5.00 | $21,810.00 | | |
| 4/20/2015 | L.P. Bavp | Major Shareholder | Sell | 30,300 | $5.03 | $152,409.00 | | |
| 4/15/2015 | L.P. Bavp | Major Shareholder | Sell | 35,800 | $5.03 | $180,074.00 | | |
| 4/14/2015 | L.P. Bavp | Major Shareholder | Sell | 18,400 | $5.01 | $92,184.00 | | |
| 4/13/2015 | L.P. Bavp | Major Shareholder | Sell | 100 | $5.00 | $500.00 | | |
| 3/6/2015 | Richard S Eiswirth Jr | CFO | Buy | 10,000 | $4.84 | $48,400.00 | | |
| 3/2/2015 | C. Daniel Myers | CEO | Sell | 2,000 | $5.21 | $10,420.00 | | |
| 1/2/2015 | C. Daniel Myers | CEO | Sell | 2,000 | $5.51 | $11,020.00 | | |
| 1/2/2015 | David Holland | SVP | Sell | 5,000 | $5.56 | $27,800.00 | | |
| 12/1/2014 | C. Daniel Myers | CEO | Sell | 2,000 | $5.99 | $11,980.00 | | |
| 12/1/2014 | David Holland | SVP | Sell | 5,000 | $5.71 | $28,550.00 | | |
| 10/27/2014 | L.P. Bavp | Major Shareholder | Sell | 57,918 | $6.34 | $367,200.12 | | |
| 10/1/2014 | C. Daniel Myers | CEO | Sell | 2,000 | $5.42 | $10,840.00 | | |
| 10/1/2014 | David Holland | SVP | Sell | 5,000 | $5.26 | $26,300.00 | | |
| 10/1/2014 | Patrick Lee | Major Shareholder | Sell | 621,191 | $5.42 | $3,366,855.22 | | |
| 9/30/2014 | Patrick Lee | Major Shareholder | Sell | 354,062 | $5.42 | $1,919,016.04 | | |
| 9/29/2014 | Patrick Lee | Major Shareholder | Sell | 240,662 | $5.47 | $1,316,421.14 | | |
| 9/11/2014 | L.P. Bavp | Major Shareholder | Sell | 2,816 | $6.25 | $17,600.00 | | |
| 9/4/2014 | L.P. Bavp | Major Shareholder | Sell | 39,500 | $6.33 | $250,035.00 | | |
| 8/29/2014 | L.P. Bavp | Major Shareholder | Sell | 7,400 | $6.27 | $46,398.00 | | |
| 8/28/2014 | L.P. Bavp | Major Shareholder | Sell | 3,000 | $6.27 | $18,810.00 | | |
| 8/1/2014 | David Holland | SVP | Sell | 5,000 | $5.64 | $28,200.00 | | |
| 7/1/2014 | David Holland | SVP | Sell | 5,000 | $6.02 | $30,100.00 | | |
| 5/1/2014 | David Holland | SVP | Sell | 5,000 | $5.93 | $29,650.00 | | |
| 3/4/2014 | C. Daniel Myers | CEO | Sell | 22,775 | $7.10 | $161,702.50 | | |
| 3/4/2014 | David Holland | SVP | Sell | 10,000 | $6.84 | $68,400.00 | | |
| 3/4/2014 | Susan Caballa | Insider | Sell | 8,931 | $7.01 | $62,606.31 | | |
| 1/16/2014 | Domain Partners Vi, L.P. | Major Shareholder | Sell | 296,760 | $6.39 | $1,896,296.40 | | |
| 7/17/2013 | Polaris Venture Management Co | Insider | Sell | 122,937 | $4.80 | $590,097.60 | | |
| 6/20/2013 | Domain Partners Vi, L.P. | Major Shareholder | Sell | 10,516 | $5.01 | $52,685.16 | | |
| 6/19/2013 | Domain Partners Vi, L.P. | Major Shareholder | Sell | 55,278 | $5.39 | $297,948.42 | | |
| 6/18/2013 | Polaris Venture Management Co | Insider | Sell | 37,063 | $5.44 | $201,622.72 | | |
| 6/17/2013 | Domain Partners Vi, L.P. | Major Shareholder | Sell | 126,709 | $5.29 | $670,290.61 | | |
| 6/11/2013 | Domain Partners Vi, L.P. | Major Shareholder | Sell | 5,337 | $5.00 | $26,685.00 | | |
| 5/17/2013 | David Holland | SVP | Sell | 30,000 | $4.13 | $123,900.00 | | |
| 5/16/2013 | Domain Partners Vi, L.P. | Major Shareholder | Sell | 44,242 | $4.60 | $203,513.20 | | |
| 12/13/2012 | Peter J Pizzo III | Director | Buy | 5,000 | $1.44 | $7,200.00 | | |
| 12/3/2012 | C. Daniel Myers | CEO | Sell | 7,700 | $1.95 | $15,015.00 | | |
(Data available from 1/1/2013 forward)
Alimera Sciences (NASDAQ ALIM) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Alimera Sciences to Present at the 8th Annual LD Micro Invitational Conference
finance.yahoo.com - May 22 at 9:18 AM |
 | Alimera Sciences (ALIM) Rating Lowered to Sell at Zacks Investment Research
www.americanbankingnews.com - May 11 at 5:43 PM |
| Alimera Sciences (ALIM) Price Target Cut to $2.50 by Analysts at HC Wainwright
www.americanbankingnews.com - May 8 at 1:41 PM |
| Brokerages Anticipate Alimera Sciences (ALIM) to Post ($0.04) Earnings Per Share
www.americanbankingnews.com - May 7 at 9:28 PM |
| Alimera Sciences (ALIM) Insider Richard S. Eiswirth, Jr. Acquires 10,000 Shares
www.americanbankingnews.com - May 7 at 8:14 PM |
 | Alimera Sciences' (ALIM) CEO Dan Myers on Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - May 6 at 9:39 AM |
| Edited Transcript of ALIM earnings conference call or presentation 3-May-18 1:00pm GMT
finance.yahoo.com - May 5 at 4:26 PM |
| Alimera Sciences, Inc. 2018 Q1 - Results - Earnings Call Slides
seekingalpha.com - May 4 at 4:28 PM |
 | BRIEF-Alimera Sciences Posts Q1 Loss Per Share Of $0.11
www.reuters.com - May 4 at 9:26 AM |
 | ALIMERA SCIENCES, INC.
www.streetinsider.com - May 4 at 9:26 AM |
| Alimera Sciences (ALIM) Lifted to Sell at ValuEngine
www.americanbankingnews.com - May 4 at 12:54 AM |
| Alimera Sciences misses by $0.05, misses on revenue
seekingalpha.com - May 3 at 9:27 AM |
| Alimera Sciences Reports First Quarter 2018 Results
finance.yahoo.com - May 2 at 4:26 PM |
| Alimera Sciences (ALIM) Set to Announce Quarterly Earnings on Monday
www.americanbankingnews.com - April 30 at 7:48 AM |
| Reader Inquiry: EyePoint Pharmaceuticals Is On A Tear, What's Going On?
seekingalpha.com - April 28 at 4:25 PM |
| Alimera Sciences (ALIM) Cut to Hold at Zacks Investment Research
www.americanbankingnews.com - April 25 at 4:04 PM |
| Alimera Sciences to Report First Quarter 2018 Results May 2, 2018
finance.yahoo.com - April 25 at 10:04 AM |
| Alimera Sciences (ALIM) Given Average Rating of "Strong Buy" by Analysts
www.americanbankingnews.com - April 20 at 1:34 PM |
| HC Wainwright Analysts Give Alimera Sciences (ALIM) a $5.00 Price Target
www.americanbankingnews.com - April 19 at 12:16 PM |
| Alimera Sciences (ALIM) Raised to "Hold" at ValuEngine
www.americanbankingnews.com - April 18 at 4:44 PM |
| Alimera Sciences (ALIM) Given a $5.00 Price Target by HC Wainwright Analysts
www.americanbankingnews.com - April 15 at 8:22 PM |
| Cowen Reiterates $3.00 Price Target for Alimera Sciences (ALIM)
www.americanbankingnews.com - April 15 at 8:22 PM |
| Alimera Sciences (ALIM) Downgraded by ValuEngine to Sell
www.americanbankingnews.com - April 15 at 7:48 PM |
| Zacks Investment Research Upgrades Alimera Sciences (ALIM) to Buy
www.americanbankingnews.com - April 10 at 8:41 AM |
| Alimera Sciences (ALIM) Downgraded by Zacks Investment Research to Hold
www.americanbankingnews.com - April 2 at 4:46 PM |
| Alimera Sciences (ALIM) Receives Consensus Recommendation of "Strong Buy" from Analysts
www.americanbankingnews.com - April 1 at 1:26 AM |
| Alimera Sciences (ALIM) Raised to "Buy" at Zacks Investment Research
www.americanbankingnews.com - March 30 at 4:32 PM |
| Zacks Investment Research Lowers Alimera Sciences (ALIM) to Hold
www.americanbankingnews.com - March 23 at 4:34 PM |
| Alimera Sciences (ALIM) Raised to Buy at Zacks Investment Research
www.americanbankingnews.com - March 22 at 4:32 PM |
| Edited Transcript of ALIM earnings conference call or presentation 1-Mar-18 2:00pm GMT
finance.yahoo.com - March 18 at 10:01 AM |
| Stonepine Capital Management LLC Grows Position in Alimera Sciences Inc (ALIM)
www.americanbankingnews.com - March 6 at 10:02 AM |
 | Global Diabetic Retinopathy Market Anticipated Growth By Increasing Incidence of Ophthalmic Complications in Diabetic Patients
www.marketwatch.com - March 5 at 10:42 AM |
 | Alimera Sciences Reports Fourth Quarter and Full Year 2017 Financial Results - GlobeNewswire (press release)
globenewswire.com - March 2 at 4:22 PM |
| Alimera Sciences (ALIM) Posts Quarterly Earnings Results, Misses Expectations By $0.07 EPS
www.americanbankingnews.com - March 1 at 11:18 AM |
| Alimera Sciences Reports Fourth Quarter and Full Year 2017 Financial Results
finance.yahoo.com - March 1 at 9:41 AM |
| Alimera Sciences, Inc. to Host Earnings Call
finance.yahoo.com - March 1 at 9:41 AM |
| Alimera Sciences to Present at the 38th Annual Cowen & Co. Health Care Conference
finance.yahoo.com - February 27 at 10:15 AM |
| Head to Head Comparison: Argos Therapeutics (ARGS) versus Alimera Sciences (ALIM)
www.americanbankingnews.com - February 25 at 1:10 AM |
| Alimera Sciences (ALIM) Scheduled to Post Quarterly Earnings on Tuesday
www.americanbankingnews.com - February 20 at 3:46 AM |
| Alimera Sciences to Report Fourth Quarter and Full Year 2017 Results on February 28, 2018
finance.yahoo.com - February 14 at 3:24 PM |
| Alimera Sciences, Inc. (ALIM) Major Shareholder Armistice Capital Master Fund Buys 20,000 Shares
www.americanbankingnews.com - February 9 at 9:08 PM |
| Alimera Sciences (ALIM) Receives "Buy" Rating from HC Wainwright
www.americanbankingnews.com - January 22 at 11:54 PM |
| Insider Selling: Alimera Sciences, Inc. (ALIM) SVP Sells 25,500 Shares of Stock
www.americanbankingnews.com - January 19 at 10:50 PM |
| Insider Selling: Alimera Sciences, Inc. (ALIM) Insider Sells 13,410 Shares of Stock
www.americanbankingnews.com - January 19 at 10:50 PM |
| Alimera Sciences, Inc. (ALIM) CEO C. Daniel Myers Sells 52,900 Shares
www.americanbankingnews.com - January 19 at 10:30 PM |
| Alimera Sciences, Inc. (ALIM) Insider Sells $17,827.62 in Stock
www.americanbankingnews.com - January 18 at 8:30 PM |
| Philip Ashman Sells 25,500 Shares of Alimera Sciences, Inc. (ALIM) Stock
www.americanbankingnews.com - January 18 at 8:30 PM |
| Insider Selling: Alimera Sciences, Inc. (ALIM) CEO Sells 52,900 Shares of Stock
www.americanbankingnews.com - January 18 at 8:00 PM |
| Strongbridge Biopharma (SBBP) vs. Alimera Sciences (ALIM) Critical Review
www.americanbankingnews.com - January 10 at 8:02 AM |
| Alimera Sciences (ALIM) Upgraded to "Hold" by Zacks Investment Research
www.americanbankingnews.com - January 8 at 9:26 PM |
Alimera Sciences (NASDAQ:ALIM) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Alimera Sciences (NASDAQ:ALIM) Income Statement, Balance Sheet and Cash Flow Statement
Alimera Sciences (NASDAQ ALIM) Stock Chart for Wednesday, May, 23, 2018
Loading chart…
